Trial
NCT03894540
Dose Escalation and Dose Expansion Study of IPN60090 in Patients With Advanced Solid Tumours
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Ipsen
Collaborators
—
Condition
Solid Tumor
Intervention
IPN60090
Why stopped
Following an internal portfolio review, Ipsen has made the decision to terminate study D-US-60090-001. Ipsen would like to highlight that early termination was not due to any safety or tolerability issues with IPN60090
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-09-13